title: Doxorubicin cardiotoxicity: response of left ventricular ejection fraction to exercise and incidence of regional wall motion abnormalities.
abstract: Gated radionuclide ventriculograms were performed to evaluate cardiac function in 53 patients who received doxorubicin treatment for various malignancies (mean dose: 449 +/- 128 mg/m2 BSA). In fourteen patients (Group I) function was evaluated before and after treatment; there was a significant decrease of resting left ventricular ejection fraction after therapy (p less than 0.001). Twenty-two patients (Group II) had serial studies during treatment which also showed a significant fall of resting left ventricular ejection fraction (p less than 0.001). Eighteen patients in Groups I and II had supine exercise studies. A normal exercise response was maintained in the majority of patients. Exercise testing added little to the diagnostic performance when compared to serial resting studies. We found regional wall motion abnormalities (mild apical hypokinesis) at rest by visual inspection in 33 of 36 Group I and Group II patients who had received doxorubicin. In the baseline or initial study, only 4 of these patients demonstrated WMA. In 18 Group I and II patients who were exercised, 3 had wall motion abnormalities during the initial study. All of these patients demonstrated wall motion abnormalities at rest after the second study, however only 7 of 18 demonstrated abnormalities during the exercise study. The results indicate that resting left ventricular ejection fraction declines after doxorubicin treatment. Exercise radionuclide angiography may not increase diagnostic accuracy for the detection of doxorubicin related cardiotoxicity. Regional wall motion abnormalities occur with a relatively high incidence following doxorubicin therapy, more readily detectable at rest. However, the exercise study can distinguish doxorubicin related wall motion abnormalities from those due to coronary artery disease.
authors.affiliation: Department of Radiological Sciences, UCLA School of Medicine 90024.
authors.forename: J H
authors.initials: JH
authors.lastname: Bae
authors.forename: M
authors.initials: M
authors.lastname: Schwaiger
authors.forename: M
authors.initials: M
authors.lastname: Mandelkern
authors.forename: A
authors.initials: A
authors.lastname: Lin
authors.forename: H R
authors.initials: HR
authors.lastname: Schelbert
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects*; D005080:Exercise Test; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D012146:Rest; D013318:Stroke Volume / Q000187:drug effects
chemical_list: D004317:Doxorubicin